share_log

Cardio Diagnostics | 8-K: Current report

Cardio Diagnostics | 8-K: Current report

Cardio Diagnostics | 8-K:重大事件
美股SEC公告 ·  2024/04/03 04:37

Moomoo AI 已提取核心訊息

Cardio Diagnostics Holdings Inc. has announced that starting from April 3, 2024, its senior management will use a new set of materials for presentations to current and potential investors. These materials are part of the March 2024 Investor Presentation, which is now incorporated into the company's Form 8-K filing with the SEC and will also be available on Cardio Diagnostics' website. The company, listed on The Nasdaq Stock Market LLC under the symbol CDIO for its common stock and CDIOW for its redeemable warrants, is classified as an emerging growth company. The information provided in the Investor Presentation is not considered filed for SEC purposes and is not incorporated by reference into any registration statement as per the Securities Exchange Act of 1934, except as explicitly stated in such filings.
Cardio Diagnostics Holdings Inc. has announced that starting from April 3, 2024, its senior management will use a new set of materials for presentations to current and potential investors. These materials are part of the March 2024 Investor Presentation, which is now incorporated into the company's Form 8-K filing with the SEC and will also be available on Cardio Diagnostics' website. The company, listed on The Nasdaq Stock Market LLC under the symbol CDIO for its common stock and CDIOW for its redeemable warrants, is classified as an emerging growth company. The information provided in the Investor Presentation is not considered filed for SEC purposes and is not incorporated by reference into any registration statement as per the Securities Exchange Act of 1934, except as explicitly stated in such filings.
Cardio Diagnostics Holdings Inc.宣佈,從2024年4月3日起,其高級管理層將使用一套新的材料向現有和潛在投資者進行演講。這些材料是2024年3月投資者演示文稿的一部分,該報告現已納入該公司向美國證券交易委員會提交的8-K表格,也將在Cardio Diagnostics的網站上公佈。該公司在納斯達克股票市場有限責任公司上市,普通股的股票代碼爲CDIO,可贖回認股權證的代碼爲CDIOW,被列爲新興成長型公司。根據1934年《證券交易法》,除非此類文件中明確規定,否則投資者簡報中提供的信息不被視爲出於美國證券交易委員會的目的提交,也未以引用方式納入任何註冊聲明中。
Cardio Diagnostics Holdings Inc.宣佈,從2024年4月3日起,其高級管理層將使用一套新的材料向現有和潛在投資者進行演講。這些材料是2024年3月投資者演示文稿的一部分,該報告現已納入該公司向美國證券交易委員會提交的8-K表格,也將在Cardio Diagnostics的網站上公佈。該公司在納斯達克股票市場有限責任公司上市,普通股的股票代碼爲CDIO,可贖回認股權證的代碼爲CDIOW,被列爲新興成長型公司。根據1934年《證券交易法》,除非此類文件中明確規定,否則投資者簡報中提供的信息不被視爲出於美國證券交易委員會的目的提交,也未以引用方式納入任何註冊聲明中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息